<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://www.huliq.com" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
 <title>progression-free survival</title>
 <link>http://www.huliq.com/tags/progression-free-survival</link>
 <description>The taxonomy view with a depth of 0.</description>
 <language>en</language>
<item>
 <title>Outcome of Progression-Free Survival May Result in Biased Trial Results</title>
 <link>http://www.huliq.com/16183/outcome-of-progression-free-survival-may-result-in-biased-trial-results</link>
 <description>Measurement of &lt;strong&gt;progression-free survival&lt;/strong&gt;, a widely used endpoint in cancer clinical trials, has methodological flaws that can lead to biased estimates. </description>
 <comments>http://www.huliq.com/16183/outcome-of-progression-free-survival-may-result-in-biased-trial-results#comments</comments>
 <category domain="http://www.huliq.com/health">Health</category>
 <category domain="http://www.huliq.com/tags/biased-trial">Biased Trial</category>
 <category domain="http://www.huliq.com/tags/cancer-clinical-trials">cancer clinical trials</category>
 <category domain="http://www.huliq.com/tags/cancer-treatment">Cancer Treatment</category>
 <category domain="http://www.huliq.com/tags/progression-free-survival">progression-free survival</category>
 <pubDate>Fri, 23 Mar 2007 04:38:05 -0500</pubDate>
 <dc:creator>harminka</dc:creator>
 <guid isPermaLink="false">16183 at http://www.huliq.com</guid>
</item>
<item>
 <title>Sutent achieves first line EAU approval for kidney cancer</title>
 <link>http://www.huliq.com/16114/sutent-achieves-first-line-eau-approval-for-kidney-cancer</link>
 <description>&lt;strong&gt;Sutent (sunitinib malate) &lt;/strong&gt;has received a European Association of Urology (EAU) recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma (mRCC).</description>
 <comments>http://www.huliq.com/16114/sutent-achieves-first-line-eau-approval-for-kidney-cancer#comments</comments>
 <category domain="http://www.huliq.com/health">Health</category>
 <category domain="http://www.huliq.com/tags/kidney-cancer">kidney cancer</category>
 <category domain="http://www.huliq.com/tags/progression-free-survival">progression-free survival</category>
 <category domain="http://www.huliq.com/tags/renal-cell-carcinoma">renal cell carcinoma</category>
 <category domain="http://www.huliq.com/tags/sunitinib-malate">sunitinib malate</category>
 <category domain="http://www.huliq.com/tags/sutent">Sutent</category>
 <pubDate>Thu, 22 Mar 2007 12:47:55 -0500</pubDate>
 <dc:creator>harminka</dc:creator>
 <guid isPermaLink="false">16114 at http://www.huliq.com</guid>
</item>
</channel>
</rss>
